CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.

CureVac N.V.

CureVac (Nasdaq: CVAC) is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing, optimizing, and manufacturing this versatile biological molecule for medical purposes. The principle of CureVac’s proprietary technology is the use of optimized mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases. In July 2020, CureVac entered in a collaboration with GSK to jointly develop new products in prophylactic vaccines for infectious diseases based on CureVac’s second-generation mRNA technology. This collaboration was later extended to the development of second-generation COVID-19 vaccine candidates, and modified mRNA vaccine technologies. Based on its proprietary technology, CureVac has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. CureVac N.V. has its headquarters in Tübingen, Germany, and has more than 1,100 employees across its sites in Germany, the Netherlands, Belgium, Switzerland and the U.S. Further information can be found at www.curevac.com.

GlaxoSmithKline

European Investment Bank

German Federal Ministry of Education and Research (BMBF)

dievini Hopp Biotech Holding

Chartwave

Baillie Gifford

Baden-Württembergische Versorgungsanstalt für Ärzte

Landeskreditbank Baden-Württemberg

LBBW Asset Management

Qatar Investment Authority

CureVac

CureVac's mRNA Breakthrough: A Potential Game-Changer in Cancer Treatment

Discover how CureVac's mRNA technology could help revolutionize cancer therapy in an exclusive interview with Dr. Myriam Mendila, Chief Development Officer at CureVac.

Read more about the promising advancements in cancer vaccines and the potential to transform treatment strategies: https://lnkd.in/ez-CeBrp

At CureVac, we believe in the power of diversity and stand firmly against any type of discrimination.

In a world where unity is paramount, we're honored to have our RNA people from various cultural backgrounds share, what diversity means to them. They expressed their thoughts in their native languages, highlighting the beauty of cultural diversity.

Let's stand together against racism and discrimination, championing diversity in every aspect of our lives. Join us in making a difference today and every day. #Zusammenland #DiversityMatters 🌍✊

CureVac is gearing up for another remarkable conference in Miami - the Jefferies on the Bay Summit, just a day after our participation at the Leerink Partners Global Biopharma Conference. Now, it's time for back-to-back action! 🚀

Our team is thrilled to engage with investors, industry leaders and experts to explore innovative strategies and collaborations shaping the future of healthcare. 💡🔬

#CureVac #Innovation #JefferiesOnTheBaySummit

🌟 We are thrilled to announce our participation at the prestigious Leerink Partners Global Biopharma Conference in Miami today! 🌟

As we work to revolutionize healthcare through our propriety mRNA technology platform, we greatly look forward to connecting with fellow industry experts and investors at this event.

#CureVac #Innovation #LeerinkConference 🚀🔬

🌟 Celebrating International Women's Day! 🌟

Today, we honor the incredible achievements, contributions, and resilience of women across the globe that have driven fundamental change and made lasting impact on this world. From breaking barriers to driving change, women continue to inspire and empower us all. Let's commit to creating a more equitable world where every woman has the opportunity to thrive.

#InternationalWomensDay #IWD2024 #Equality #Empowerment #DiversityandInclusion

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue	12.87M -	17.42M 35.31%	48.90M 180.78%	102.99M 110.61%	67.42M 34.54%	52.70M 21.84%
cost of revenue	17.74M -	27.98M 57.70%	14.17M 49.35%	238.19M 1,580.63%	183.99M 22.76%	321.28M 74.61%
gross profit	-4.87M -	-10.57M 116.85%	34.73M 428.64%	-135.21M 489.34%	-116.57M 13.78%	-268.58M 130.40%
selling and marketing expenses	1.08M -	1.75M 61.75%	733K 58.23%	1.74M 137.79%	417K 76.08%
general and administrative expenses	20.41M -	42.18M 106.63%	45.03M 6.75%	87.20M 93.66%	88.99M 2.06%
selling general and administrative expenses	21.50M -	43.94M 104.36%	45.76M 4.15%	88.94M 94.36%	89.41M 0.53%
research and development expenses	41.72M -	43.24M 3.64%	113.81M 163.19%	815.91M 616.92%	62.55M 92.33%
other expenses	4.73M -	1.75M 62.99%	-870K 149.71%	-627.79M 72,060.11%	-17.68M 97.18%	-1 100.00%
cost and expenses	85.69M -	116.91M 36.43%	158.70M 35.74%	515.25M 224.67%	318.27M 38.23%	321.28M 0.94%
operating expenses	67.95M -	88.93M 30.87%	158.70M 78.45%	277.06M 74.58%	134.28M 51.53%	-1 100.00%
interest expense	275K -	1.46M 430.91%	22.10M 1,413.90%	10.34M 53.23%	3.71M 64.14%
ebitda	-67.08M -	-91.50M 36.42%	-109.80M 20.00%	-386.49M 251.99%	-223.10M 42.27%	-268.58M 20.38%
operating income	-72.82M -	-99.50M 36.63%	-124.00M 24.63%	-412.26M 232.46%	-249.46M 39.49%	-268.58M 7.67%
depreciation and amortization	3.78M -	8.00M 111.50%	14.20M 77.59%	25.78M 81.50%	26.36M 2.24%
total other income expenses net	1.69M -	-627K 137.03%	-5.80M 824.72%	-235K 95.95%	302K 228.51%	13.91M 4,505.61%
income before tax	-71.13M -	-100.13M 40.76%	-129.80M 29.64%	-412.50M 217.80%	-249.16M 39.60%	-254.67M 2.21%
income tax expense	110K -	-252K 329.09%	-726K 188.10%	-782K 7.71%	-126K 83.89%	-254.67M 202,019.47%
net income	-71.24M -	-99.87M 40.19%	-129.07M 29.24%	-411.72M 218.98%	-249.03M 39.51%
weighted average shs out	175.97M -	186.91M 6.22%	132.20M 29.27%	186.01M 40.71%	189.07M 1.65%
weighted average shs out dil	175.97M -	186.91M 6.22%	132.20M 29.27%	186.01M 40.71%	189.07M 1.65%
eps	-0.40 -	-0.53 32.50%	-0.98 84.91%	-2.21 125.51%	-1.32 40.27%
epsdiluted	-0.40 -	-0.53 32.50%	-0.98 84.91%	-2.21 125.51%	-1.32 40.27%

COM:CUREVAC

CureVac

Last Close

2.71

05/11 21:00

Market Cap

697.59M

Beta: -

Volume Today

743.49K

Avg: -

Preview